People In Brief
This article was originally published in The Tan Sheet
Hennessey jumps to Prestige from Pfizer
You may also be interested in...
EC drug goes nonprescription in Ireland
The House Committee on Science and Technology will consider legislation crafted to provide strategic direction to the federal research program for nanotechnology
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.